Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.30 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15184809 | 1.00 | HTR7 (0.32) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL15184779 | 0.87 | MAPT (0.35) | — | |
| SCHEMBL864259 | 0.84 | PIK3CD (0.41) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL15184790 | 0.84 | PIK3CD (0.41) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL863980 | 0.79 | MAPT (0.30) | — | |
| SCHEMBL15875847 | 0.78 | OPRK1 (0.40) | OPRK1ALDH1A1 | |
| SCHEMBL713421 | 0.78 | OPRK1 (0.40) | OPRK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL863359 | 0.77 | TERT (0.32) | OPRK1 | |
| SCHEMBL864178 | 0.77 | HTR7 (0.39) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL15184778 | 0.77 | HTR7 (0.39) | HTR7ADRA1DADRA1AADRA1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | HTR7 1818/4885ADRA1D 3469/4885ADRA1A 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.